The FDA has accepted for priority review the sBLA for lisocabtagene maraleucel to treat relapsed/refractory MZL.

Continued approval of zongertinib may be contingent upon verification of clinical benefit in a confirmatory trial.

Survey results suggest that some patients with multiple myeloma may forgo treatment that improves progression-free survival (PFS) if it also increases the risk of adverse events and fails to improve ...

The executive order outlines some of the steps the Trump administration has already taken to delay or withhold federal funding and terminate existing grants. However, those actions have been ...

The HHS secretary has canceled nearly $500 million in grants and contracts intended to support mRNA vaccine development.

The One Big Beautiful Bill Act will have negative impacts on cancer patients, oncologists, and the health care system at large, experts say.

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of certain patients with diffuse midline glioma.

Recent news reports highlight uncertainty about pharmaceutical tariffs, an error-prone AI tool in use at the FDA, and scientific research funding in jeopardy.

Resection beyond contrast-enhancing tumor margins is associated with superior outcomes in patients with primary glioblastoma, a study suggests.

The FDA has expanded the approved indication of IV Avtozma to include the treatment of CRS in patients 2 years of age and older.

Future prospective studies will be necessary to assess potential causation of sucralose in driving immunotherapy resistance as well as to determine how other demographic factors, including location ...

Designating GG1 on biopsy as noncancer without considering the prognostic values of adverse clinical features may lead to undertreatment and an increased risk of cancer-specific death in men with ...